Monterey, California, August 10, 2026
Elevation Spine announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Saber-XA™, an expandable anterior lumbar interbody fusion (ALIF) system designed to provide surgeons with greater intraoperative flexibility during spinal fusion procedures. The system combines expandable cage technology with a zero-profile, FDA-cleared anterior lumbar plate, allowing surgeons to customize implant height and lordotic angle according to patient anatomy during surgery. The clearance represents an important milestone for Elevation Spine as it expands its integrated fixation technology platform for spinal procedures.
Saber-XA Enables Intraoperative Implant Customization
The Saber-XA expandable system is designed to address the need for flexibility in anterior lumbar fusion by enabling independent adjustment of implant height and lordotic angle during surgery. According to Elevation Spine, the technology provides an extensive range of configurations within the implant’s expansion range, allowing surgeons to make adjustments based on actual patient anatomy rather than relying solely on predetermined static implant dimensions. The system also incorporates a separately applied zero-profile anterior lumbar plate positioned away from major blood vessels rather than directly anterior to the spinal column. Surgeons can select between inline spike fixation and self-drilling screw options using a single instrument tray, supporting procedural flexibility and potentially simplifying operating-room workflow. The company stated that the system was designed to provide surgeons with greater intraoperative customization and optionality while reducing constraints associated with conventional static ALIF implants. This approach is intended to support spinal alignment objectives while giving surgical teams greater control over implant positioning and configuration during lumbar fusion procedures.
3D-Printed Titanium Design Reduces Inventory Complexity
Saber-XA incorporates 3D-printed titanium endplates and is offered in three footprints with three sizes per footprint. The company says this results in nine total implant sizes while providing access to a broad range of height and lordosis configurations, including hyperlordotic options. By integrating adjustability into the implant itself, Saber-XA is designed to reduce the number of individual implant choices required for a procedure compared with static ALIF systems that may require substantially larger inventories. This configuration could help simplify surgical inventory management and operating-room preparation, while allowing surgeons to tailor the implant during the procedure. The system’s expandable architecture and integrated fixation approach represent the company’s broader strategy of combining interbody support and fixation technologies within a streamlined surgical platform.
Advertisement
FDA Clearance Supports Expansion of Saber Technology
The FDA 510(k) clearance provides a significant regulatory milestone for Elevation Spine and supports the commercial introduction of Saber-XA in the United States. The Saber-XA Anterior Lumbar Plate is described by the company as a zero-profile anterior lumbar plate that underwent testing to demonstrate its ability to independently support the spinal column. The clearance adds another application to Elevation Spine’s Saber Technology platform, which integrates zero-profile anterior plate fixation with interbody support across cervical and lumbar spine procedures. Elevation Spine is focused on developing spinal medical devices and integrated-fixation technologies intended to simplify surgical workflows and support patient outcomes. The company’s Saber platform combines interbody support and anterior fixation technologies, with Saber-XA extending this approach into expandable lumbar fusion. The latest FDA clearance positions the device for use in the U.S. market and highlights continued innovation in spinal surgery, implant design, and intraoperative customization. For the MedTech sector, the introduction of Saber-XA demonstrates how expandable implant technologies can provide surgeons with additional options during complex spinal procedures while potentially reducing the logistical burden associated with maintaining numerous static implant configurations. The FDA clearance therefore represents both a regulatory achievement for Elevation Spine and a further development in advanced spinal fusion technology.
Source: Elevation Spine press release
